Send to

Choose Destination
Hum Mol Genet. 2018 Sep 15;27(18):3272-3282. doi: 10.1093/hmg/ddy233.

TNNT1 nemaline myopathy: natural history and therapeutic frontier.

Author information

Clinic for Special Children, Strasburg, PA, USA.
Department of Pediatrics, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA.
Diagnostic Referral Division, Nemours/Alfred I. duPont Hospital for Children, Wilmington, DE, USA.
Department of Physiology, Wayne State University School of Medicine, Detroit, MI, USA.
Department of Pathology and Laboratory Medicine and Neuroscience Research Center, The Medical College of Wisconsin, Milwaukee, WI, USA.
Audentes Therapeutics, San Francisco, CA, USA.


We describe the natural history of 'Amish' nemaline myopathy (ANM), an infantile-onset, lethal disease linked to a pathogenic c.505G>T nonsense mutation of TNNT1, which encodes the slow fiber isoform of troponin T (TNNT1; a.k.a. TnT). The TNNT1 c.505G>T allele has a carrier frequency of 6.5% within Old Order Amish settlements of North America. We collected natural history data for 106 ANM patients born between 1923 and 2017. Over the last two decades, mean age of molecular diagnosis was 16 ± 27 days. TNNT1 c.505G>T homozygotes were normal weight at birth but failed to thrive by age 9 months. Presenting neonatal signs were axial hypotonia, hip and shoulder stiffness, and tremors, followed by progressive muscle weakness, atrophy and contractures. Affected children developed thoracic rigidity, pectus carinatum and restrictive lung disease during infancy, and all succumbed to respiratory failure by 6 years of age (median survival 18 months, range 0.2-66 months). Muscle histology from two affected children showed marked fiber size variation owing to both Type 1 myofiber smallness (hypotrophy) and Type 2 fiber hypertrophy, with evidence of nemaline rods, myofibrillar disarray and vacuolar pathology in both fiber types. The truncated slow TNNT1 (TnT) fragment (p.Glu180Ter) was undetectable in ANM muscle, reflecting its rapid proteolysis and clearance from sarcoplasm. Similar functional and histological phenotypes were observed in other human cohorts and two transgenic murine models (Tnnt1-/- and Tnnt1 c.505G>T). These findings have implications for emerging molecular therapies, including the suitably of TNNT1 gene replacement for newborns with ANM or other TNNT1-associated myopathies.

[Available on 2019-09-15]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center